Bajaj Healthcare Ltd

₹

- close price

bajajhealth.com BSE: 539872 NSE: BAJAJHCARE

About

Incorporated in 1993, Bajaj Healthcare Ltd manufactures a wide range of Active Pharmaceutical Ingredients and Formulations^[1]

Key Points

Business Overview:^[1]^[2]^[3]
BHL is focused on development, supply, manufacturing of Amino Acids, Nutritional Supplements and Active Pharma Ingredients for Pharmaceutical, Nutraceuticals and Food industries. It manufactures active pharmaceutical ingredients and formulations in the form of tablets, capsules, powder, etc. for ~550+ clients, exporting bulk drugs to ~62+ countries in Europe, USA, Africa, Australia, etc.

Website BSE NSE

Market Cap ₹ Cr.
Current Price ₹
High / Low ₹ /
Stock P/E
Book Value ₹
Dividend Yield %
ROCE %
ROE %
Face Value ₹

Add ratio to table

Edit ratios

Pros

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE Allcap

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Figures in Rs. Crores




Operating Profit
OPM %

Interest
Depreciation
Profit before tax
Tax %

EPS in Rs
Raw PDF

Profit & Loss

Figures in Rs. Crores




Operating Profit
OPM %

Interest
Depreciation
Profit before tax
Tax %

EPS in Rs
Dividend Payout %

Compounded Sales Growth
10 Years:	%
5 Years:	%
3 Years:	%
TTM:	%

Compounded Profit Growth
10 Years:	%
5 Years:	%
3 Years:	%
TTM:	%

Stock Price CAGR
10 Years:	%
5 Years:	%
3 Years:	%
1 Year:	%

Return on Equity
10 Years:	%
5 Years:	%
3 Years:	%
Last Year:	%

Balance Sheet

Figures in Rs. Crores


Equity Capital
Reserves


Total Liabilities

CWIP
Investments

Total Assets

Cash Flows

Figures in Rs. Crores





Net Cash Flow
Free Cash Flow
CFO/OP

Ratios

Figures in Rs. Crores


Debtor Days
Inventory Days
Days Payable
Cash Conversion Cycle
Working Capital Days
ROCE %

Insights

In beta

Mar 2014

Mar 2015

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Revenue Mix - API Segment
Percentage ・Standalone data

	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	xx.xx	x.xx	xx.xx	xx.xx
xxx	xxx	xxx			xxx	xxx	xxx	xxx	xxx	xxx	xxx
			xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
		x,xxx	xxx	xxx		xxx	xxx	x,xxx	x,xxx		xxx
xx.xx	xx.xx	xx.xx				xxx.xx	xx.xx	xx.xx	xx.xx		xxx.xx
										xx	xx
											xxx

Please log in to see hidden values.

Revenue Mix - Formulation Segment
Percentage ・Standalone data

Installed Capacity - API & Intermediates
MT/Month ・Standalone data

Export Revenue Share
Percentage ・Standalone data

Employee Count (Total Workforce)
Number ・Standalone data

Installed Capacity - Formulations (FDF)
Mn units/month ・Standalone data

Total Drug Master Files (DMF) Filed
Number ・Standalone data

Opium Gum Processing Capacity
MTPA ・Standalone data

Shareholding Pattern

Numbers in percentages

4 Recently

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	67.49%	67.69%	67.73%	67.74%	67.74%	59.19%	59.19%	59.19%	59.19%	59.19%	59.19%	58.29%
	0.69%	0.66%	0.74%	0.53%	0.00%	1.07%	1.01%	1.05%	1.09%	1.12%	1.18%	1.53%
	0.34%	0.43%	0.48%	0.43%	0.00%	1.97%	2.36%	2.52%	3.16%	2.99%	2.96%	2.91%
	31.48%	31.22%	31.06%	31.31%	32.27%	37.77%	37.45%	37.25%	36.56%	36.70%	36.67%	37.26%
No. of Shareholders	27,322	28,008	29,626	32,712	32,397	31,995	32,672	35,710	35,980	38,576	37,953	37,696

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	67.26%	67.26%	67.26%	67.26%	67.26%	67.26%	67.49%	67.74%	59.19%	58.29%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.38%	0.78%	0.53%	1.05%	1.53%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.34%	0.43%	2.52%	2.91%
	32.74%	32.74%	32.74%	32.74%	32.74%	32.36%	31.38%	31.31%	37.25%	37.26%
No. of Shareholders	151	116	99	1,031	7,236	30,723	26,037	32,712	35,710	37,696

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

DRHP

Credit ratings

Concalls

Dec 2025

Transcript

AI Summary
PPT
Oct 2025

Transcript

AI Summary
PPT
Jul 2025

Transcript

AI Summary
PPT
Jun 2022

Transcript

AI Summary
PPT
Aug 2020

Transcript

AI Summary
PPT